You can receive independent, expert advice on alcohol treatment and alcohol rehab centres by telephoning DryOutNow.com on 0845 370 0203

The most important consideration in choosing the type of treatment for alcohol addiction is to match the individual to the alcohol treatment that is most likely to lead to a successful outcome.

DryOutNow.com can provide an assessment of all your needs and a recommendation regarding the most effective alcohol treatment for you, given your particular circumstances. We can provide fast, immediate access to alcohol treatment.

Alkermes, Inc. recently announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system (CNS) disorders. ALKS 33 is the company's first novel, small molecule drug candidate to enter the clinic. The molecule builds on Alkermes' scientific expertise in brain reward pathways as well as the company's clinical and commercial knowledge in the field of addiction. In addition, Alkermes initiated a clinical pharmacokinetic study to further explore ALKS 29, a potential oral treatment for alcohol dependence.

The phase 1 randomised, double-blind, placebo-controlled study for ALKS 33 will enrol 16 healthy volunteers and is designed to assess the pharmacokinetics, safety and tolerability of ALKS 33 following single oral administration at escalating dose levels. The company expects to report top-line results from the study in the first half of calendar 2009. Initiation of this trial is based on recent data from preclinical studies that showed ALKS 33 demonstrated statistically superior oral efficacy compared to naltrexone. The studies also suggested that ALKS 33 is not readily metabolised by the liver, a unique advantage over existing oral therapies for addiction.

"There are few medications available to help patients struggling to overcome addictions and new treatment options are desperately needed," said Elliot Ehrich, M.D., chief medical officer of Alkermes. "We believe that the addiction field will evolve in a similar way to other CNS markets, such as mental illnesses, where treatments include both oral and injectable medications. This flexible approach offers patients and doctors the option to build the most appropriate therapies into treatment programs and fit the needs of individual patients."

As part of the company's strategy, Alkermes is planning additional preclinical studies of ALKS 33 for other CNS disorders and has also initiated a phase 1 study of ALKS 29, a potential oral treatment for alcohol dependence. The open-label crossover study is designed to assess the pharmacokinetics, safety and tolerability of ALKS 29 compared to an oral control. The company expects to report top-line results from the study in the first half of calendar 2009.

The development of these two candidates further underscores the significant expertise in and commitment to the area of addiction at Alkermes. VIVITROL®, the company's first commercial product in addiction, is currently approved for the treatment of alcohol dependence in the U.S. and Russia. VIVITROL is the only once-monthly injectable medication approved for the treatment of alcohol dependence.

Article published on 30/12/2008 by DryOutNow.com

DryOutNow.com provides highly practical help for people with alcohol problems, their friends and relatives. DryOutNow.com also provides free resources for healthcare professionals such as medical information and alcohol treatment guidelines.

• Technology improves treatment options for drug users ...... read
• Department promoting early substance use screening process ...... read
• Alcohol tax increases deter drinking ...... read
• DrugScope welcomes report on 'neglected issue' of prescription and over-the-counter medication depen ...... read
• DrugScope responds to NTA figures on young people in treatment for substance misuse ...... read
• Concerns over trends in Ketamine use ...... read
• Try science when 'just saying no' isn't enough ...... read
• More action needed to tackle alcohol misuse, says BMA ...... read
• Alkermes initiates clinical trial for ALKS 33, a novel oral molecule with potential benefits in addi ...... read
• Genetic markers identified for alcohol response in UCSF Gallo study ...... read
• NIDA Monitoring the Future Survey, Results published ...... read
• Technology can help addicts trying to quit ...... read
• Study assesses success of anti meth adverts ...... read
• All patients should be asked about alcohol and drug abuse, says The American College of Obstetrician ...... read
• Researchers must tap into the language of intoxication ...... read
• Report points to lack of public awareness of health guidelines ...... read
• Reward stress link points to new targets for treating addiction ...... read
• SAMHSA releases new data on drug related hospital emergency department visits ...... read
• National rates of co occurring substance use and mental disorders call for better integration of men ...... read
• Study will seek to break cycle of chemical dependence and incarceration ...... read

• Pablo and FRANK - the new cocaine campaign ...... read
• Cannabis upgraded to Class B drug ...... read
• DrugScope welcomes report on 'neglected issue' of prescription and over-the-counter medication depen ...... read
• Tougher health and safety law demands tougher drugs policies, says drug testing company ...... read
• Time's up for irresponsible drink deals ...... read